二甲双胍联合孕激素用于子宫内膜肿瘤保留生育治疗：FELICIA 试验带来的启示
Posted innews OB/GYN & Women's Health Oncology

Adjunctive Metformin with Progestin in Fertility-Sparing Treatment of Endometrial Neoplasia: Insights from the FELICIA Trial

The FELICIA phase IIb trial found that adding metformin to progestin therapy for fertility-sparing treatment in endometrial neoplasia did not improve 3-year recurrence-free survival or remission rates, though some reproductive outcomes favored metformin. Safety was consistent with known profiles.
Posted innews OB/GYN & Women's Health Oncology

Expanding the Genetic Landscape in Ovarian Carcinoma: Insights from the PERSONA-Ovary Trial on Germline and Somatic Testing

The PERSONA-Ovary trial demonstrates the feasibility and clinical value of unselected germline multigene panel testing alongside somatic BRCA analysis in ovarian carcinoma, revealing a 29.7% pathogenic variant prevalence and optimal testing strategies for integrating genetics into routine care.
Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers
Posted innews OB/GYN & Women's Health Oncology

Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers

This phase 1/2 study evaluates farletuzumab ecteribulin, a folate receptor alpha-targeting ADC, showing that fractionated dosing reduces interstitial lung disease risk and demonstrates preliminary antitumor activity in advanced ovarian, endometrial, triple-negative breast, and lung cancers.
Racial and Ethnic Disparities in Treatment Initiation and Survival Among Patients With Endometrial Cancer: Socioeconomic Modifiers and Clinical Implications
Posted inClinical Updates news OB/GYN & Women's Health Oncology

Racial and Ethnic Disparities in Treatment Initiation and Survival Among Patients With Endometrial Cancer: Socioeconomic Modifiers and Clinical Implications

This review synthesizes recent evidence demonstrating persistent racial and ethnic disparities in treatment initiation and survival among patients with advanced endometrial cancer, highlighting the critical influence of socioeconomic status and social determinants on outcomes.
Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Evaluating Periconception Exposure and Perinatal Outcomes
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Evaluating Periconception Exposure and Perinatal Outcomes

GLP-1 receptor agonists are increasingly used in women of reproductive age, but their safety during periconception and pregnancy remains unclear. Current observational data show no definitive harm, yet robust evidence is lacking, emphasizing individualized counseling and further research.